Yukong antidepressant to begin clinical trials in first quarter.
YUKONG YKP10A ANTIDEPRESSANT TO ENTER CLINICAL TRIALS IN FIRST QUARTER, following approval of an IND for the drug on Dec. 20. It is the first IND for the company and the first for a Korean company in the U.S., Yukong said. Yukong is planning to develop YKP10A through Phase I on its own but anticipates seeking either a joint venture or a licensing agreement to bring the drug into Phase II. Yukong worked with the contract research organization IBRD-Rostrom on the application.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth